Claims

1. Use of a sialic acid binding molecule in the manufacture of a medicament for modulating cell growth and/or cell activity.

2. The use of claim 1, wherein the medicament is for modulating one or more of cell viability, cell migration, cell metabolism, cell differentiation and/or cell morphology/phenotype.

3. Use of a sialic acid binding molecule in the manufacture of a medicament for treating and/or preventing a disease and/or condition caused, contributed to and/or characterised by aberrant cell growth, differentiation, proliferation and/or activity.

4. The use of claim 3, wherein the diseases which are caused, contributed to or characterised by aberrant cell growth, differentiation, proliferation and/or activity are selected from the group consisting of cell proliferation and/or differentiation disorders; and cancer.

5. Use of a sialic acid binding molecule in the manufacture of a medicament for the treatment and/or prevention of cancer.

6. The use of claims 4 or 5, wherein the cancer is lung cancer, cervical cancer, colon cancer and/or breast cancer.

7. The use of any preceding claim, wherein the sialic acid binding molecule comprises one or more family 40 carbohydrate binding module(s).

8. The use of any preceding claim, wherein the sialic acid binding molecule comprises the sialic acid binding domain of *Vibrio cholerae* NanH sialidase and/or the sialic acid binding domain of *Streptococcus pneumoniae* NanA sialidase.

9. The use of claim 8, wherein the *Vibrio cholerae* NanH sialidase comprises the amino acid sequence of SEQ ID NO: 1 or 2.

10. The use of claim 8, wherein the *Streptococcus pneumoniae* NanA sialidase comprises the amino acid sequence of SEQ ID NO: 3 or 4.

11. The use of any preceding claims, wherein the sialic acid binding molecule is a multimeric CBM.

12. The use of claim 11, wherein the multimeric CBM comprises two or more *Vibrio cholerae* NanH sialidases and/or two or more *Streptococcus pneumoniae* NanA sialidases.

13. The use of claim 11 or 12, wherein the multimeric CBM comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 *Vibrio cholerae* NanH sialidases and/or *Streptococcus pneumoniae* NanA sialidases.

14. The use of any one of claims 11, 12 or 13, wherein the multimeric CBM is *Vc*4CBM, *Vc*2CBMTD and/or *Sp*2CBMTD.

15. Use of a sialic acid binding molecule in the manufacture of a medicament for the treatment and/or prevention of cancer, wherein the sialic acid binding molecule comprises:

(i) one or more sialic acid binding domain(s) of *Vibrio cholerae* NanH sialidase and/or one or more sialic acid binding domain(s) of *Streptococcus pneumoniae* NanA sialidase;

(ii) a multimeric CBM;

(iii) a multimeric CBM comprising two or more *Vibrio cholerae* NanH sialidases and/or two or more *Streptococcus pneumoniae* NanA sialidases; and/or

(iv) *Vc*4CBM, *Vc*2CBMTD and/or *Sp*2CBMTD.

16. An *in vitro* method of modulating cell growth and/or cell activity, said method comprising contacting a cell or population of cells with a sialic acid binding molecule so as to modulate cell growth and/or cell activity.